Preprints.org
June 28, 2021
Maurizio Coppola, Francesco Bevione, Raffaella Mondola
1 citation
preprint
Psychedelics extracted by plants have been used in religious, spiritual and mystic practices for millennia. In 1957, Dr. Hofmann have identified and synthesized the prodrug psilocybin, a substance present in more than 200 species of psychedelic mushrooms. Although the limitations related to the scientific design of many studies, clinical observations performed during the 1950s and the 1960s...
June 27, 2021
Annie M. Mccartney, Hugh McGovern, Alexander de Foe
preprint
Psychedelic substances such as psilocybin and ketamine may represent the future of antidepressant treatment, due to their rapid and prolonged effects on mood and cognition. The current body of psychedelic research has focused on administration and treatment within a psychiatric context. Here, instead, we put to the test the contention that it is necessary to evaluate the current state of this...
Canadian Journal of Health Technologies
June 24, 2021
Yi‐sheng Chao, Jennifer Horton
5 citations
Two systematic reviews, 3 randomized controlled trials, and 2 single-arm safety trials were identified that evaluated several combinations of psychedelic-assisted psychotherapy. Psilocybin was the psychedelic most tested. Other psychedelics identified in the systematic reviews and primary studies were 3,4-methylenedioxymethamphetamine (or MDMA), lysergic acid diethylamide (or LSD), ayahuasca...
OBM Neurobiology
June 24, 2021
Sarah-Catherine Rodan, Phillip Aouad, Iain S. Mcgregor et al.
10 citations
Anorexia Nervosa (AN) is a major health problem with one of the highest mortalities and treatment costs of any psychiatric condition. Cognitive behavioural therapy (CBT) is currently the most widely used treatment for AN in adults but provides remission rates ≤ 50%. Treatment drop-out is exceedingly high and those that persevere with treatment often relapse, causing increased risk of morbidity...
Irish Journal of Medical Science
June 15, 2021
Kate Corrigan, Maeve Haran, Conor Mccandliss et al.
79 citations
Abstract Introduction Despite the rapid advance of psychedelic science and possible translation of psychedelic therapy into the psychiatric clinic, very little is known about mental health service user attitudes. Objectives To explore mental health service user attitudes to psychedelics and psilocybin therapy. Methods A questionnaire capturing demographics, diagnoses, previous psychedelic and...
Perspectives In Psychiatric Care
June 8, 2021
Dina Fradkin
3 citations
The use of psychedelics, such as psilocybin, has emerged in recent literature as a novel therapeutic treatment for various psychiatric disorders, including substance use, depression, and anxiety. While international and domestic trials are currently underway, there is data demonstrating both the relative safety and potential efficacy of psilocybin. Psychiatric mental health nurse practitioners...
Journal of Psychopharmacology
May 29, 2021
Pedro J. Teixeira, Matthew W. Johnson, Christopher Timmermann et al.
87 citations
Healthful behaviours such as maintaining a balanced diet, being physically active and refraining from smoking have major impacts on the risk of developing cancer, diabetes, cardiovascular diseases and other serious conditions. The burden of the so-called ‘lifestyle diseases’—in personal suffering, premature mortality and public health costs—is considerable. Consequently, interventions designed...
Mental Health Weekly
May 28, 2021
The use of psychedelics is evolving for the treatment of a variety of mental illnesses, including anxiety, depression, post‐traumatic stress disorder and other related uses, Financial News Media reported May 25. Some psychedelic drugs are extracted from plants or mushrooms, and some are synthetic (human‐made). These drugs are now considered effective for patients with treatment‐resistant...
May 19, 2021
Evan Lewis-Healey, Ruben Laukkonen, Michiel van Elk
4 citations
preprint
Objective: Recent clinical trials have demonstrated that psilocybin may have strong antidepressant effects, and may be effective in the treatment of depressive disorders when embedded in a psychotherapeutic protocol (psilocybin-assisted psychotherapy; PAP). However, despite promising results, the mechanism(s) that may be responsible for the antidepressant effects of PAP remain contested. Within...
Electronic Journal of General Medicine
April 27, 2021
Hisham Alshaikhli, Redhwan Ahmed Al-Naggar, Gwen Erlam
14 citations
Introduction: Psilocybin mushroom use is well documented in spiritual and religious ceremonies globally. This drug is now the most popular in Europe and the USA. \nObjective: The objective of this study is to explore the experiences and effects of psilocybin on patients with depression and anxiety. \nMethod: A qualitative study was conducted interviewing ten participants currently taking...